Logo image of ALTS

ALT5 SIGMA CORP (ALTS) Stock Fundamental Analysis

NASDAQ:ALTS - Nasdaq - US47089W1045 - Common Stock - Currency: USD

9.89  +1.01 (+11.37%)

Premarket: 10.15 +0.26 (+2.63%)

Fundamental Rating

2

Overall ALTS gets a fundamental rating of 2 out of 10. We evaluated ALTS against 197 industry peers in the Pharmaceuticals industry. ALTS has a bad profitability rating. Also its financial health evaluation is rather negative. ALTS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year ALTS has reported negative net income.
ALTS had a positive operating cash flow in the past year.
ALTS had negative earnings in 4 of the past 5 years.
In multiple years ALTS reported negative operating cash flow during the last 5 years.
ALTS Yearly Net Income VS EBIT VS OCF VS FCFALTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -7.58%, ALTS is in the better half of the industry, outperforming 72.08% of the companies in the same industry.
ALTS has a Return On Equity of -25.24%. This is in the better half of the industry: ALTS outperforms 67.51% of its industry peers.
Industry RankSector Rank
ROA -7.58%
ROE -25.24%
ROIC N/A
ROA(3y)-8.77%
ROA(5y)-34.52%
ROE(3y)-9.86%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALTS Yearly ROA, ROE, ROICALTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

ALTS has a Gross Margin of 50.22%. This is in the better half of the industry: ALTS outperforms 61.93% of its industry peers.
In the last couple of years the Gross Margin of ALTS has grown nicely.
The Profit Margin and Operating Margin are not available for ALTS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 50.22%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y31.18%
GM growth 5Y17.71%
ALTS Yearly Profit, Operating, Gross MarginsALTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

More info and screens

2

2. Health

2.1 Basic Checks

ALTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALTS has more shares outstanding
ALTS has more shares outstanding than it did 5 years ago.
ALTS has a worse debt/assets ratio than last year.
ALTS Yearly Shares OutstandingALTS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
ALTS Yearly Total Debt VS Total AssetsALTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of 0.59, we must say that ALTS is in the distress zone and has some risk of bankruptcy.
ALTS's Altman-Z score of 0.59 is in line compared to the rest of the industry. ALTS outperforms 57.36% of its industry peers.
ALTS has a debt to FCF ratio of 7.28. This is a slightly negative value and a sign of low solvency as ALTS would need 7.28 years to pay back of all of its debts.
ALTS has a Debt to FCF ratio of 7.28. This is amongst the best in the industry. ALTS outperforms 81.73% of its industry peers.
ALTS has a Debt/Equity ratio of 0.52. This is a neutral value indicating ALTS is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.52, ALTS is not doing good in the industry: 60.41% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF 7.28
Altman-Z 0.59
ROIC/WACCN/A
WACC9.84%
ALTS Yearly LT Debt VS Equity VS FCFALTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

2.3 Liquidity

A Current Ratio of 0.85 indicates that ALTS may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.85, ALTS is doing worse than 86.29% of the companies in the same industry.
ALTS has a Quick Ratio of 0.85. This is a bad value and indicates that ALTS is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.85, ALTS is doing worse than 78.68% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.85
Quick Ratio 0.85
ALTS Yearly Current Assets VS Current LiabilitesALTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for ALTS have decreased strongly by -25.77% in the last year.
Measured over the past years, ALTS shows a very negative growth in Revenue. The Revenue has been decreasing by -18.62% on average per year.
EPS 1Y (TTM)-25.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.57%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-32.08%
Revenue growth 5Y-18.62%
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALTS Yearly Revenue VS EstimatesALTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2024 20M 40M 60M 80M 100M

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ALTS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALTS Price Earnings VS Forward Price EarningsALTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

77.16% of the companies in the same industry are more expensive than ALTS, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 97.12
EV/EBITDA N/A
ALTS Per share dataALTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ALTS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALT5 SIGMA CORP

NASDAQ:ALTS (5/29/2025, 8:00:00 PM)

Premarket: 10.15 +0.26 (+2.63%)

9.89

+1.01 (+11.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-01 2025-05-01
Earnings (Next)08-18 2025-08-18
Inst Owners7.03%
Inst Owner Change0%
Ins Owners5.38%
Ins Owner Change23.08%
Market Cap172.58M
Analysts0
Price TargetN/A
Short Float %2.9%
Short Ratio2.95
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.77
P/FCF 97.12
P/OCF 97.12
P/B 6.98
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.6
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.1
FCFY1.03%
OCF(TTM)0.1
OCFY1.03%
SpS0.72
BVpS1.42
TBVpS-1.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.58%
ROE -25.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 50.22%
FCFM 14.18%
ROA(3y)-8.77%
ROA(5y)-34.52%
ROE(3y)-9.86%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y31.18%
GM growth 5Y17.71%
F-Score5
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF 7.28
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.85
Quick Ratio 0.85
Altman-Z 0.59
F-Score5
WACC9.84%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.57%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y-32.08%
Revenue growth 5Y-18.62%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-59.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y21.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.46%
OCF growth 3YN/A
OCF growth 5YN/A